Table 2

Patient characteristics at the start of treatment in Lund compared with other centres. The numbers and values relate to the treatments—that is, a patient may be included more than once

Lund patient (n=142)Other centres patient (n=227)
Number%Number%Level of sign
*p<0.05; **p<0.01; ***p<0.001; †treatment without any other DMARD.
Number of treatment regimens153100251100
Female1167620481
Monotherapy†493214457***
Severely destroyed (expected HAQ reduction 20%)382516064***
Continuing systemic glucocorticoid treatment1258219879
MeanSDMeanSD
Disease duration (years)14.59.814.610.1
Age (years)55.013.157.013.5
Previous DMARDs4.11.94.32.2
Continuing DMARDs0.900.70.50.6***
Continuing prednisolone dosage (mg/week)44.932.944.836.9
DAS285.81.15.51.1*
HAQ1.480.611.520.64
ESR (mm/1st h)44.228.935.922.7**
CRP (mg/l)38.034.545.340.6